The present invention relates to methods of treating cancer in a patient by administering a compound useful as an inhibitor of ATR protein kinase in combination with a compound useful as an inhibitor of Chk1 protein kinase. The aforementioned combination displays a surprising synergistic effect in treating cancer despite the targeted protein kinases being within the same biological pathway. Moreover, the present invention also relates to methods of treating cancer by administering a compound useful as an inhibitor of ATR protein kinase; administering a compound useful as an inhibitor of Chk1 protein kinase; as well as administering a DNA damaging agent to a patient.
The compounds utilized in this invention are represented by formula I and formula II:
wherein the variables are as defined herein.
本发明涉及通过施用一种可作为 ATR 蛋白激酶
抑制剂的化合物和一种可作为 Chk1 蛋白激酶
抑制剂的化合物来治疗患者癌症的方法。尽管靶向蛋白激酶属于同一
生物通路,但上述组合在治疗癌症方面显示出惊人的协同效应。此外,本发明还涉及治疗癌症的方法,即给患者施用一种可作为 ATR 蛋白激酶
抑制剂的化合物;给患者施用一种可作为 Chk1 蛋白激酶
抑制剂的化合物;以及给患者施用一种 DNA 损伤剂。
本发明中使用的化合物由式I和式II表示:
其中变量如本文所定义。